CLCatherine Lhommé

Catherine Lhommé

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Catherine Lhommé has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic Significance of Serum Alphafoetoprotein Early Decline in Ovarian Yolk Sac Tumor

    by T.La Motte De Rouge, P. Pautier, P. Duvillard, A. Rey, P. Morice, C. Haie Meder, P. Kerbrat, S. Culine, K. Fizazi, C. Lhomme

    Aim: Ovarian yolk sac tumor (OYST) is a very rare malignancy arising in young women. Due to the rarity of this tumor, only few retrospective series have been published. We recently reported one of the largest series on outcome in OYSTs pts. Here, we aimed to evaluate the serum alphafoetoprotein (AFP) early decline which might help to make appropriate risk-based decision about therapy. Methods: This retrospective study is based on prospectively recorded OYST cases at the Institut Gustave-Roussy (IGR). Pediatric cases were excluded. Survival curves were estimated by the Kaplan-Meier method. Serum AFP decline was calculated with the formula applied at IGR in poor prognosis germ cell tumor. Pts were classified in either favorable or unfavorable decline. Univariate analysis using the log-rank test tested possible associations between survival and patient or disease covariates. Multivariate analysis was performed using a model of logistic regression. Results: Between 1976 and 2006, 84 pts were registered. Data on AFP were available to calculate AFP early decline for 57 pts. Median post-operative AFP was 1040 (2 - 116 539) ng/mL. Most of the pts (48/57) have undergone fertility-sparing surgery. Cisplatin-based chemotherapy was given 56/57 pts and 42/57 pts received bleomycin, etoposide and cisplatin (BEP) regimen. Overall 5-year and event-free survival rates were 82% and 81%, respectively. The disease stage, presence of ascites at presentation, BEP regimen, serum AFP half-life and early AFP decline were significantly predictive factors. Overall survival in pts with favorable AFP decline was 96% whereas it was 49% in pts with unfavorable decline (p < 0.001). In the multivariate model only the absence of ascites at initial diagnosis and serum AFP decline were significantly associated with a better overall survival. Conclusions: Serum AFP early decline help to identify poor prognosis ovarian YSTs pts. This may be relevant for the management of OYSTs since it has been shown in a phase III study (GETUG 13) in testicular poor prognosis germ cell tumor that early switch to a dose dense chemotherapy regimen for pts with slow tumor marker decline reduces the risk of progression or death. Disclosure: All authors have declared no conflicts of interest.


  • Open Access

    SP-0505: New imaging modalities

    by C. Balleyguier, C. Haie-Meder, P. Morice, E. Zareski, C. Lhomme, S. Taieb

  • 8003 ORAL Experience With Bevacizumab in the Management of Relapsed Ovarian Cancer – a Retrospective Observational Study in Five French Hospitals

    by C. Dubot, G.A. Emile, C. Lhomme, I. Asmane, P. Pautier, J. Alexandre, F. Goldwasser, E. Pujade Lauraine, I. Ray Coquard, F. Seile

  • 8049 POSTER Epithelial Ovarian Carcinoma in Very Young Women: Age-specific Characteristics

    by J. Michels, A. Rey, P. Duvillard, P. Morice, O. Caron, G. Leteuff, A. Savoye, S. Gouy, C. Lhomme, P. Pautier

  • Results from a randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON).

    by C. Lhomme, D. Berton-Rigaud, F. Joly, J. Baurain, F. Rolland, A. Stenzl, T. Schmelter, M. Campone

    9116 Background: Sagopilone, a novel, fully synthetic epothilone, has shown significant activity in a broad range of preclinical tumor models and in phase II studies in ovarian cancer (OC) and castrate-refractory prostate cancer (CRPC). Peripheral neuropathy (PN) is the most clinically relevant toxicity of sagopilone. Several studies have suggested that acetyl-L-carnitine (ALC) may prevent chemotherapy-induced PN. The REASON study is the first randomized, prospective, placebo-controlled study to investigate the safety, efficacy, and pharmacokinetics of sagopilone plus ALC for the prevention of sagopilone-induced PN. Methods: Patients (pts) with advanced refractory or relapsed OC or CRPC and no evidence of neuropathy received sagopilone (16 mg/m2 i.v. over 3 h every 3 wk) with either ALC (1,000 mg p.o. 3 times a day) or placebo (PBO) for ≤6 cycles until 1 month after the last sagopilone infusion. Primary endpoint was the incidence of PN determined by pt and investigator assessment; electromyography was performed if grade 2 PN occurred. Results: From August 2008, 150 pts were enrolled over 11 months (98 with OC, 52 with PC; 75 pts ALC, 75 pts PBO). Evaluable pts received ≥1 treatment cycle (n=121). Median duration of treatment (4 cycles, ALC; 5 cycles, PBO) and overall incidence of PN were similar between treatment groups. Incidence of high-grade PN was lower in the ALC group in both tumor types and statistically lower in OC pts (p=0.04). PN onset occurred within the first treatment cycle for 60% of ALC and 52% of PBO pts, with a similar median duration (grades 1-4 PN: 184 days, ALC; 191 days, PBO). There was no notable difference in discontinuations due to adverse events between the 2 groups (20 ALC, 23 PBO). Conclusions: No significant difference in overall PN incidence was observed between treatment groups. However, in OC pts the incidence of high-grade PN was significantly lower in the ALC group compared with the PBO group.


  • Prognosis and prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma).

    by C. Uzan, M. Koskas, S. Gouy, P. Pautier, C. Lhomme, C. Balleyguier, C. Haie-Meder, P. Duvillard, P. Morice

    5096 Background: To determine the prognosis and prognostic factors in a large series of mucinous borderline tumors of the ovary (MBOT). Methods: A retrospective review of patients with MBOT treated or referred to our institution. Three inclusion criteria were defined: 1. centralized histological review by our expert pathologist; 2. exclusion of peritoneal pseudomyxoma and any synchronous malignant tumor in the abdominal cavity; 3. available data on the management and outcomes of patients. Results: From 1997 to 2004, 97 patients fulfilled inclusion criteria (95 stage I and 2 stage II disease). Nine patients had endocervical-like subtypes. Eight patients had stromal microinvasion and 24, intraepithelial carcinoma. Radical and conservative surgeries were performed respectively in 28 and 69 patients. After a median follow-up of 48 months, 13 patients had developed 14 recurrences: 7 were borderline and 7 were invasive lesions. The probability of recurrence in the form of carcinoma, 5 and 10 years after the diagnosis was respectively 9% and 13%. The only prognostic factor for recurrence attaining statistical significance was the use of a cystectomy (compared to other surgeries RR = 5.6; p = 0.003; compared to salpingo-oophorectomy RR = 5.5; p = 0.012). Conclusions: In the present series of 97 MBOT, mainly early-stage disease and excluding peritoneal pseudomyxoma, the cumulative risk of recurrence in the form of invasive carcinoma at 10 years was 13%. MBOT do not appear to be such a safe disease. The only prognostic factor for recurrence was the use of a cystectomy suggesting that a salpingo-oophorectomy should be preferred in case of conservative treatment. No significant financial relationships to disclose.

  • Chimiothérapie de première ligne des adénocarcinomes ovariens de stades avancés

    by C. Lhommé, C. Even, P. Morice, C Balleyguier, M.C. Petrella, S. Gouy, C. Uzan, P. Duvillard, P. Pautier

    The treatment of the advanced ovarian adenocarcinoma, most frequently stage at diagnostic, relies on association of surgery and chemotherapy. The current standard is the association carboplatine-paclitaxel. In spite of this treatment, relapses are frequent, and the prognosis thus remains very reserved. Presently the current areas of research aim at both improving the efficiency of treatments and decreasing their toxicity. So the various trials dealt with the use of the other cytotoxics having proved efficiency against relapses either in double-agent therapy or in association in the current standard, or in the administration of the chemotherapy by intra peritoneal way. They also investigated the possibility of pursuing the therapeutic sequence by a treatment of maintenance or consolidation. As for numerous cancerous pathologies, the targeted therapies, notably the antiangiogenic one, represent an important hope in the treatment of the ovarian cancer.


    • 1 December 2008
      • p. 12S51-12S55

    [Lymphadenectomy for uterine cancer].

    by S Gouy, C Uzan, Y Zafrani, C Lhommé, P Pautier, P Duvillard, C Haie-Meder, P Morice

    Uterine cancer can metastasize to both the pelvic and para-aortic levels. No one questions the diagnostic and prognostic value of lymphadenectomy, but its therapeutic value is still open to debate. In early cervical cancer (4 cm is radiotherapy. A pre-radiation laparoscopy to investigate lymph node involvement at the lumbo-aortic level may help to define the extent of the radiation field. For endometrial cancer, the role and benefit of lymphadenectomy are much less clear since these patients often have major co-morbidities which increase the risk of complications from an extended lymph node dissection.

  • Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer

    by Catherine Lhommé, Florence Joly, Joan L. Walker, Andrea A. Lissoni, Maria O. Nicoletto, Gregory M. Manikhas, Mark M.O. Baekelandt, Alan N. Gordon, Paula M. Fracasso, William L. Mietlowski, et al.

    Purpose: To compare the safety and efficacy of carboplatin and paclitaxel administered with or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with advanced ovarian or primary peritoneal cancer. Patients and Methods: Seven hundred sixty-two patients with stage IV or suboptimally debulked stage III ovarian or primary peritoneal cancer were randomly assigned to receive either valspodar 5 mg/kg every 6 hours for 12 doses, paclitaxel 80 mg/m2, and carboplatin area under the curve (AUC) 6 (PC-PSC; n = 381) or paclitaxel 175 mg/m2 and carboplatin AUC 6 (PC; n = 381). Time to disease progression (TTP) was the primary end point. Secondary end points were overall survival time (OS), response rate (RR), safety, and tolerability. Results: With a median follow-up of 736 days (range, 1 to 2,280 days), the median TTP was 13.2 and 13.5 months in the PC-PSC and PC groups, respectively (P = .67); the median OS was 32 and 28.9 months, respectively (P = .94). The overall RR was higher in the PC group (41.5% v 33.6%; P = .02). Central and peripheral nervous system and GI toxicities were more common in the PC-PSC group. Ataxia occurred in 53.5% and 3.2% of PC-PSC–and PC-treated patients, respectively. Febrile neutropenia occurred more frequently in the PC-PSC group. More PC-PSC–treated patients discontinued therapy because of adverse events (AEs), experienced serious AEs, and required paclitaxel dose reductions. Conclusion: The addition of valspodar to PC did not improve TTP or OS and was more toxic compared with PC in untreated patients with advanced ovarian or primary peritoneal cancer.


  • Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy: Correlation of radiological findings with histology of the cervix

    by P. Morice, E. Vincens, C. Balleyguier, A. Rey, C. Uzan, E. Zareski, Y. Zafrani, P. Pautier, C. Lhommé, D. Castaigne, et al.

    16524 Background: The evaluation of residual disease (RD) after chemoradiation therapy (CRT) in stage IB2/II cervical carcinoma is conventionally based on clinical and radiological examinations (particularly Magnetic Resonance Imaging/MRI) performed 4 to 8 weeks after the end of treatment. Very few specific papers have correlated MRI and histological findings in cervix cancer. This is the aim of the present study. Methods: A retrospective review was undertaken of patients fulfilling the following inclusion criteria: 1. stage IB2/II cervical cancer 2. external radiotherapy (45 Gy) with concomitant chemotherapy (cisplatin 40 mg/m2/week) followed by utero-vaginal brachytherapy (15Gy to the intermediate risk CTV); 3. MRI performed 4 to 8 weeks after brachytherapy and 4. completion surgery including at least a hysterectomy. Post-surgical histological findings and MRI results were compared. Results: Forty-four patients (17 stage IB2 and 27 stage II) treated between 2003 and 2006 fulfilled all the inclusion criteria. Twelve patients (27%) had achieved a radiological complete response, 16 (36.5%) had unclassified lesions (RD or “fibrosis”) and 16 (36.5%) had radiological residual tumor. In terms of histological results, 19 patients (43%) had no residual disease, 10 (23%) had minimal residual disease (isolated cells or measuring a few millimeters), 2 (5%) had residual disease < 1 cm and 13 (29%) had residual disease > 1 cm. The sensitivity and the specificity of MRI in evaluating residual disease > 1 cm were respectively 87% and 52%. Conclusions: Residual disease evaluation 4 to 8 weeks after CRT with MRI is difficult and the risk of false positive result is higher than in case of MRI staging before treatment in patients with stage IB2/II cervical cancer. Other procedures or MRI improvement, such as MRI diffusion, should be evaluated for more accurate detection of residual disease in patients at the end of CRT. No significant financial relationships to disclose.